Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs.

Lipid-based vesicles are a very promising approach to treat diseases such as cancer, chronic infections and auto-immunity. Modern drug encapsulation methods allow efficient packing of therapeutic substances inside liposomes, thereby reducing the systemic toxicity of the drugs. Specific targeting can enhance the therapeutic effect of the drugs through their accumulation at the diseased site. In the vaccine field, the integration of functional viral envelope proteins into liposomes has led to an antigen carrier and delivery system termed a virosome, a clinically proven vaccine platform for subunit vaccines with an excellent immunogenicity and tolerability profile.

[1]  Sophie Pautot,et al.  Engineering asymmetric vesicles , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[2]  F. Reig,et al.  Pentapeptide YIGSR-mediated HT-1080 fibrosarcoma cells targeting of adriamycin encapsulated in sterically stabilized liposomes. , 2004, Journal of biomedical materials research. Part A.

[3]  V. Awasthi,et al.  Neutral and Anionic Liposome-Encapsulated Hemoglobin: Effect of Postinserted Poly(ethylene glycol)-distearoylphosphatidylethanolamine on Distribution and Circulation Kinetics , 2004, Journal of Pharmacology and Experimental Therapeutics.

[4]  R. Zurbriggen.  Immunostimulating reconstituted influenza virosomes. , 2003, Vaccine.

[5]  P. Gangadharam,et al.  Efficacy of liposomal budesonide in experimental asthma. , 2003, The Journal of allergy and clinical immunology.

[6]  F. Szoka,et al.  pH-induced destabilization of phosphatidylethanolamine-containing liposomes: role of bilayer contact. , 1984, Biochemistry.

[7]  S. Fischer,et al.  Localization of a new neutralizing epitope on the mumps virus hemagglutinin-neuraminidase protein. , 2001, Virus research.

[8]  K. Gelmon,et al.  Pharmacodynamic Behavior of Liposomal Antisense Oligonucleotides Targeting Her-2/neu and Vascular Endothelial Growth Factor in an Ascitic MDA435/LCC6 Human Breast Cancer Model , 2004, Cancer biology & therapy.

[9]  T. Allen,et al.  Ligand-targeted liposomal anticancer drugs. , 2003, Progress in lipid research.

[10]  P. Opolon,et al.  In vivo study of the GC90/IRIV vaccine for immune response and autoimmunity into a novel humanised transgenic mouse , 2003, British Journal of Cancer.

[11]  D. Crommelin,et al.  Targeting influenza virosomes to ovarian carcinoma cells , 2001, FEBS letters.

[12]  B. García,et al.  Liposome‐entrapped D. pteronyssinus vaccination in mild asthma patients: effect of 1‐year double‐blind, placebo‐controlled trial on inflammation, bronchial hyper‐responsiveness and immediate and late bronchial responses to the allergen , 2002, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[13]  M. Zignani,et al.  Current status of pH-sensitive liposomes in drug delivery. , 2000, Progress in lipid research.

[14]  A. Seelig,et al.  IRIV-adjuvanted hepatitis A vaccine: in vivo absorption and biophysical characterization. , 2000, Progress in lipid research.

[15]  M. Wauben,et al.  Complete remission of experimental arthritis by joint targeting of glucocorticoids with long-circulating liposomes. , 2003, Arthritis and rheumatism.

[16]  Y. Barenholz,et al.  Development of liposomal anthracyclines: from basics to clinical applications. , 1998, Journal of controlled release : official journal of the Controlled Release Society.

[17]  M. Bally,et al.  Controlling the Physical Behavior and Biological Performance of Liposome Formulations Through Use of Surface Grafted Poly(ethylene Glycol) , 2002, Bioscience reports.

[18]  Mathias Winterhalter,et al.  Protein encapsulation in liposomes: efficiency depends on interactions between protein and phospholipid bilayer. , 2002, BMC biotechnology.

[19]  N. Templeton.  Cationic Liposomes as In Vivo Delivery Vehicles , 2003 .

[20]  B. Rothen‐Rutishauser,et al.  Targeting her-2/neu with antirat Neu virosomes for cancer therapy. , 2002, Cancer research.

[21]  R. Glück,et al.  Immunogenicity of IRIV- versus alum-adjuvanted diphtheria and tetanus toxoid vaccines in influenza primed mice. , 1999, Vaccine.

[22]  V. Torchilin,et al.  Tat peptide-mediated intracellular delivery of liposomes. , 2003, Methods in enzymology.

[23]  G. Szot,et al.  Targeting and Blocking B7 Costimulatory Molecules on Antigen-Presenting Cells Using CTLA4Ig-Conjugated Liposomes: In Vitro Characterization and in Vivo Factors Affecting Biodistribution , 2003, Pharmaceutical Research.

[24]  Vivian Charles McAlister,et al.  Liposomal tacrolimus lotion as a novel topical agent for treatment of immune‐mediated skin disorders: experimental studies in a murine model , 2002, The British journal of dermatology.

[25]  Y. Kaneda,et al.  Genetic modification of cold-preserved renal grafts using HSP70 or bcl-2 HVJ-liposome method. , 2003, Transplant immunology.

[26]  J. Wilschut,et al.  Influenza virosomes: combining optimal presentation of hemagglutinin with immunopotentiating activity. , 2003, Vaccine.

[27]  N. Hirashima,et al.  Remarkable induction of apoptosis in cancer cells by a novel cationic liposome complexed with a bcl-2 antisense oligonucleotide. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[28]  J. Wilschut,et al.  Delivery of Protein Antigens to the Immune System by Fusion-Active Virosomes: A Comparison with Liposomes and ISCOMs , 2002, Bioscience reports.

[29]  M. Dewhirst,et al.  The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors. , 2001, Advanced drug delivery reviews.

[30]  E. Padovan,et al.  Influenza virosomes enhance class I restricted CTL induction through CD4+ T cell activation. , 2004, Vaccine.

[31]  J. Levy,et al.  Evaluation of genetic immunization adjuvants to improve the effectiveness of a human immunodeficiency virus type 2 (HIV-2) envelope DNA vaccine. , 2004, DNA and cell biology.

[32]  M. Dellian,et al.  Novel Temperature-Sensitive Liposomes with Prolonged Circulation Time , 2004, Clinical Cancer Research.

[33]  Robert J. Lee,et al.  Formulation kit for liposomal doxorubicin composed of lyophilized liposomes. , 2003, Anticancer research.

[34]  Hiroyuki Honda,et al.  Antitumor effects of combined therapy of recombinant heat shock protein 70 and hyperthermia using magnetic nanoparticles in an experimental subcutaneous murine melanoma , 2003, Cancer Immunology, Immunotherapy.

[35]  Suh-Chin Wu,et al.  The domain III fragment of Japanese encephalitis virus envelope protein: mouse immunogenicity and liposome adjuvanticity. , 2003, Vaccine.

[36]  E. Waelti,et al.  Delivery to cancer cells of antisense L‐ myc oligonucleotides incorporated in fusogenic, cationic‐lipid‐reconstituted influenza‐virus envelopes (cationic virosomes) , 1998, International journal of cancer.

[37]  Jian Yi Li,et al.  Organ-specific gene expression in the rhesus monkey eye following intravenous non-viral gene transfer. , 2003, Molecular vision.

[38]  T. Allen,et al.  Improved Outcome When B-Cell Lymphoma Is Treated with Combinations of Immunoliposomal Anticancer Drugs Targeted to Both the CD19 and CD20 Epitopes , 2004, Clinical Cancer Research.

[39]  G. Zuber,et al.  Towards synthetic viruses. , 2001, Advanced drug delivery reviews.

[40]  R. Gold,et al.  Intravenous Liposomal Prednisolone Downregulates In Situ TNF-α Production by T-cells in Experimental Autoimmune Encephalomyelitis , 2003, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[41]  A. Tari,et al.  Cellular Pharmacology of P-ethoxy Antisense Oligonucleotides Targeted to Bcl-2 in a Follicular Lymphoma Cell Line , 2003, Leukemia & lymphoma.

[42]  R. Zinkernagel,et al.  T helper cell‐independent neutralizing B cell response against vesicular stomatitis virus: Role of antigen patterns in B cell induction? , 1995, European journal of immunology.

[43]  R. Glück,et al.  Novel approaches in the development of immunopotentiating reconstituted influenza virosomes as efficient antigen carrier systems. , 2003, Vaccine.

[44]  J. Viret,et al.  Virosomal adjuvanted antigen delivery systems , 2003, Expert review of vaccines.

[45]  P. Marrack,et al.  Liposomal clodronate as a novel agent for treating autoimmune hemolytic anemia in a mouse model. , 2003, Blood.

[46]  Hong-Sung Kim,et al.  Effect of lipid compositions on gene transfer into 293 cells using Sendai F/HN-virosomes. , 2002, Journal of biochemistry and molecular biology.

[47]  F. Szoka,et al.  Steric stabilization of fusogenic liposomes by a low-pH sensitive PEG--diortho ester--lipid conjugate. , 2001, Bioconjugate chemistry.

[48]  M. Bally,et al.  Effective induction of CD8+ T-cell response using CpG oligodeoxynucleotides and HER-2/neu-derived peptide co-encapsulated in liposomes. , 2003, Vaccine.

[49]  J. Ruysschaert,et al.  Properties of HIV membrane reconstituted from its recombinant gp160 envelope glycoprotein. , 1992, AIDS research and human retroviruses.

[50]  Y. Shoji,et al.  Current status of delivery systems to improve target efficacy of oligonucleotides. , 2004, Current pharmaceutical design.

[51]  D. Scheinberg,et al.  Engineered Liposomes for Potential α-Particle Therapy of Metastatic Cancer , 2004 .

[52]  H. Kim,et al.  Enhanced cytotoxicity of doxorubicin encapsulated in liposomes with reconstituted Sendai F-proteins. , 2001, Journal of microencapsulation.

[53]  J. Shoji,et al.  Preparation of Virosomes Coated with the Vesicular Stomatitis Virus Glycoprotein as Efficient Gene Transfer Vehicles for Animal Cells , 2004, Microbiology and immunology.

[54]  T. Allen,et al.  Development of Fab' fragments of anti-GD(2) immunoliposomes entrapping doxorubicin for experimental therapy of human neuroblastoma. , 2003, Cancer letters.

[55]  T. Tumpey,et al.  Development of a Virosome Vaccine for Newcastle Disease Virus , 2003, Avian diseases.

[56]  F. Szoka,et al.  Chemical approaches to triggerable lipid vesicles for drug and gene delivery. , 2003, Accounts of chemical research.

[57]  A. Bangham,et al.  Cation Permeability of Phospholipid Model Membranes: Effect of Narcotics , 1965, Nature.

[58]  R. Schiffelers,et al.  Liposome-encapsulated aminoglycosides in pre-clinical and clinical studies. , 2001, The Journal of antimicrobial chemotherapy.

[59]  G. Storm,et al.  TARGETED LIPOSOMES FOR DELIVERY OF PROTEIN-BASED DRUGS INTO THE CYTOPLASM OF TUMOR CELLS , 2002, Journal of liposome research.

[60]  J H Senior,et al.  Fate and behavior of liposomes in vivo: a review of controlling factors. , 1987, Critical reviews in therapeutic drug carrier systems.

[61]  K. Matthay,et al.  Versatility in lipid compositions showing prolonged circulation with sterically stabilized liposomes. , 1992, Biochimica et biophysica acta.

[62]  R. Mischler,et al.  Inflexal V a trivalent virosome subunit influenza vaccine: production. , 2002, Vaccine.

[63]  T. Allen,et al.  Targeted delivery system for antisense oligonucleotides: a novel experimental strategy for neuroblastoma treatment. , 2003, Cancer letters.

[64]  M. Bally,et al.  In Vitro and in Vivo Characterization of Doxorubicin and Vincristine Coencapsulated within Liposomes through Use of Transition Metal Ion Complexation and pH Gradient Loading , 2004, Clinical Cancer Research.

[65]  D. Crommelin,et al.  Liposomes and ISCOMs. , 2003, Vaccine.

[66]  Markus S. Mueller,et al.  Induction of Parasite Growth-Inhibitory Antibodies by a Virosomal Formulation of a Peptidomimetic of Loop I from Domain III of Plasmodium falciparum Apical Membrane Antigen 1 , 2003, Infection and Immunity.

[67]  T. Heath,et al.  FORMATION OF VIROSOMES FROM INFLUENZA SUBUNITS AND LIPOSOMES , 1975, The Lancet.

[68]  N. Düzgüneş.  Preparation and quantitation of small unilamellar liposomes and large unilamellar reverse-phase evaporation liposomes. , 2003, Methods in enzymology.

[69]  R. Glück,et al.  Influenza virosomes are an efficient delivery system for respiratory syncytial virus-F antigen inducing humoral and cell-mediated immunity. , 2002, Vaccine.

[70]  A. Allison,et al.  Liposomes as immunological adjuvants , 1974, Nature.

[71]  Jun Yoshida,et al.  Human gene therapy for malignant gliomas (glioblastoma multiforme and anaplastic astrocytoma) by in vivo transduction with human interferon beta gene using cationic liposomes. , 2004, Human gene therapy.

[72]  Daniel Scherman,et al.  Physicochemical optimisation of plasmid delivery by cationic lipids , 2004, The journal of gene medicine.

[73]  Mitsuhiro Nishida,et al.  Liposomes with differential lipid components exert differential adjuvanticity in antigen-liposome conjugates via differential recognition by macrophages. , 2004, Bioconjugate chemistry.

[74]  K. Nohga,et al.  Efficacy of immunoliposomes on cancer models in a cell-surface-antigen-density-dependent manner , 2003, British Journal of Cancer.

[75]  S. Cryz,et al.  Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A. , 1992, The Journal of clinical investigation.

[76]  W. Pichler,et al.  In vitro studies of core peptide-bearing immunopotentiating reconstituted influenza virosomes as a non-live prototype vaccine against hepatitis C virus. , 2002, International immunology.

[77]  T. Allen,et al.  Pharmaco attributes of dioleoylphosphatidylethanolamine/cholesterylhemisuccinate liposomes containing different types of cleavable lipopolymers. , 2004, Pharmacological research.

[78]  Jeong-Sook Park,et al.  Enhancement of polyethylene glycol (PEG)‐modified cationic liposome‐mediated gene deliveries: effects on serum stability and transfection efficiency , 2003, The Journal of pharmacy and pharmacology.

[79]  L. Puttagunta,et al.  Antisense oligonucleotides to Syk kinase: a novel therapeutic approach for respiratory disorders. , 2003, Current opinion in investigational drugs.

[80]  V. Torchilin,et al.  TAT-liposomes: a novel intracellular drug carrier. , 2003, Current protein & peptide science.

[81]  L. Huang,et al.  Some negatively charged phospholipid derivatives prolong the liposome circulation in vivo. , 1992, Biochimica et biophysica acta.

[82]  K. Anam,et al.  A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice. , 2004, Vaccine.

[83]  M. Sabatino,et al.  Tumour-associated antigen (TAA)-specific cytotoxic T cell (CTL) response in vitro and in a mouse model, induced by TAA-plasmids delivered by influenza virosomes. , 2001, European journal of cancer.

[84]  T. Yoshikawa,et al.  Continuous Release of Interleukin-2 from Liposomal IL-2 (Mixture of Interleukin-2 and Liposomes) After Subcutaneous Administration to Mice , 2003, Drug development and industrial pharmacy.

[85]  G. Elliott,et al.  Intercellular Trafficking and Protein Delivery by a Herpesvirus Structural Protein , 1997, Cell.